Combination therapy using belinostat and pralatrexate to treat lymphoma
US11439643B2 · kind B2 · utility
0Cited by
5References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 14, 2016 |
| Grant date | Sep 13, 2022 |
| Priority date | — |
| Expiry date | Jun 14, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.